RT Journal Article
SR Electronic
T1 Validation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) for the Hand and Foot in a Randomized Placebo-controlled Trial
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP jrheum.141010
DO 10.3899/jrheum.141010
A1 Daniel Glinatsi
A1 Paul Bird
A1 Frederique Gandjbakhch
A1 Philip J.  Mease
A1 Pernille Bøyesen
A1 Charles G.  Peterfy
A1 Philip G.  Conaghan
A1 Mikkel Østergaard
YR 2015
UL http://www.jrheum.org/content/early/2015/10/23/jrheum.141010.abstract
AB Objective To assess changes following treatment and the reliability and responsiveness to change of the Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) in a randomized controlled trial. Methods Forty patients with PsA randomized to either placebo or abatacept (ABA) had MRI of either 1 hand (n = 20) or 1 foot (n = 20) at baseline and after 6 months. Images were scored blindly twice by 3 independent readers according to the PsAMRIS (for synovitis, tenosynovitis, periarticular inflammation, bone edema, bone erosion, and bone proliferation). Results Inflammatory features improved numerically but statistically nonsignificantly in the ABA group but not the placebo group. Baseline intrareader intraclass correlation coefficients (ICC) were good (≥ 0.50) to very good (≥ 0.80) for all features in both hand and foot. Baseline interreader ICC were good (ICC 0.72–0.96) for all features, except periarticular inflammation and bone proliferation in the hand and tenosynovitis in the foot (ICC 0.25–0.44). Intrareader and interreader ICC for change scores varied. Guyatt’s responsiveness index (GRI) was high for inflammatory features in the hand and metatarsophalangeal joints (GRI –0.67 to –3.13; bone edema not calculable). Minimal change and low prevalence resulted in low ICC and GRI for bone damage. Conclusion PsAMRIS showed overall good intrareader agreement in the hand and foot, and inflammatory feature scores were responsive to change, suggesting that PsAMRIS may be a valid tool for MRI assessment of hands and feet in PsA clinical trials.